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Abstract Calcium/calmodulin-dependent protein kinase II 
(CaM kinase II) has been proposed to play a key role in glucose 
stimulated insulin secretion. Using the rapid amplification of 
cDNA ends technique we amplified the 3' end of the CaM kinase 
II y gene from human islet RNA. A novel cDNA was detected 
composed of 5' sequence from the human CaM kinase II y gene 
joined to the 3' end of the human signal recognition particle 72 
(SRP72) gene. We predict that this mRNA species will code for a 
truncated form of CaM kinase II, designated YSRP, comprising 
the entire catalytic and regulatory domains of the protein and 
with a predicted molecular weight of 37 kDa. We mapped the 
human SRP72 gene to chromosome 18 and, as the CaM kinase 
II y gene was previously mapped to human chromosome 10q22, 
we suggest this novel cDNA may have resulted from trans-
splicing. 
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1. Introduction 
It is well established that a rise in intracellular free Ca 2 + 
plays a key role in glucose-stimulated insulin secretion [1-3] 
but the cellular events linking increased Ca 2 + concentration to 
the release of insulin are unknown. One possible mediator is 
calcium/calmodulin-dependent protein kinase II (CaM kinase 
II) [4]. C a M kinase II is a ubiquitous serine/threonine protein 
kinase which has been implicated in diverse effects of hor-
mones and neurotransmitters that utilise Ca 2 + as a second 
messenger, ranging from muscle contraction, secretion, synap-
tic transmission to gene expression (for review see [5]). The 
enzyme is an oligomeric protein of MT 500-600 k D a com-
posed of distinct but related subunits arranged in a hub-
and-spoke pattern and comprises a multigene family in which 
each of the isoforms (a, ß, y, and 8) is encoded by a separate 
gene. Cells can contain more than a single isoform of the 
kinase, and it is likely that both homomultimers and hetero-
multimers of the kinase exist. Alternatively spliced variants of 
each subunit, differing in insertions or deletions within the 
variable and association domains of the enzyme, are expressed 
in different tissues [6,7], suggesting tissue-specific functions for 
each isoform or combination of isoforms. 
Evidence for the involvement of a C a M kinase in insulin 
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secretion has been obtained by studies in which the inhibition 
of insulin release by the diabetogenic agents alloxan [8] and 
dehydrouramil [9] was correlated with the inhibition of ß-cell 
C a M kinase activity. Insulin release has also been shown to be 
inhibited by the C a M kinase II inhibitor KN-62 [10,11]. These 
findings are however confused by additional effects of alloxan 
and KN-62 on glucokinase [12] and Ca 2 +-channel activity 
[11], respectively. More convincing evidence was provided by 
the patch clamp technique; a specific peptide inhibitor of 
C a M kinase II (residues 290-309) markedly reduced insulin 
secretion from a single cell determined by capacitance meas-
urements without affecting the Ca 2 + current [13]. Further-
more, glucose has been shown to activate C a M kinase II in 
isolated rat islets and the extent of activation correlates closely 
with insulin secretion [14,15]. 
Western analysis and c D N A cloning have demonstrated the 
expression of a number of different isoforms of C a M kinase II 
in rodent islets and ß-cell lines [6,15-18]. We have previously 
reported the cloning of a partial c D N A encoding the y iso-
form of C a M kinase II from human islets [19]. In this study 
we isolated the 3 ' end of the y C a M kinase II gene from 
human islet R N A using the rapid amplification of c D N A 
ends (RACE) technique and demonstrate the expression of a 
novel truncated isoform of CaM kinase II in human islets of 
Langerhans 
2. Materials and methods 
2.1. Materials 
The human islets were supplied by Dr. Derek Grey, Islet Trans-
plantation Laboratory, Churchill Hospital, Oxford and the human 
islet cDNA library by Dr. Hiroshi Sakura, University Laboratory 
of Physiology, Oxford. The somatic cell hybrid mapping panel was 
supplied by the Human Genome Mapping Project (HGMP) resource 
centre, Hinxton Hall, Cambridge. Nucleotide sequencing was carried 
out using the dideoxy chain termination method with the Sequenase 
version 2.0 system (Amersham Life Sciences) on both strands. Taq 
DNA polymerase was purchased from Perkin Elmer and all other 
reagents were from Promega or Sigma except where specified other-
wise. 
2.2. Rapid amplification of cDNA ends 
Amplification of the 3' end of the human CaM kinase II gene from 
human islet RNA was carried out using Clontech's 3' AmpliFINDER 
RACE system. Single stranded cDNA was prepared from 25 ng of 
poly A* RNA following the manufacturer's instructions and one 
twentieth of this reaction was used as the target for two rounds of 
nested PCR. The nucleotide sequences of the primers used were de-
rived from the CaM kinase II y cDNA partial sequences previously 
isolated from a human islet cDNA library [19] (GenBank accession 
No. U66064). Primer 1 (PI) (5'-AAGCGCATCACGGCTGAC-
CAGGCTC-3') corresponded to nucleotides 817-836 and primer 2 
(P2) (5'-TCCACGGTGGCATCCATGAT-3') to nucleotides 878-
897 of the library clone. Thirty-two cycles of amplification were car-
ried out using lui (5 units) of Taq DNA polymerase for each of four 
independent RACE reactions. Each cycle consisted of 60 s denaturing 
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at 95°C, 120 s annealing at 60°C and 180 s extension at 72°C. One ul 
of the primary PCR reaction was used as the target for the secondary 
PCR reaction. 
2.3. Polymerase chain reaction (PCR) 
PCR primers were designed that would amplify a region of the 
CaM kinase II "/SRP isoform (see below), spanning the junction of 
the human SRP72 sequence and the human CaM kinase II sequence 
(sense primer = 5'-GAGAAAACTGAAGGGTGCCA-3', antisense 
primer = 5'-TAACTCCTCTATGCTTCTC-3'). Thirty-two cycles of 
amplification were carried out with one unit of Taq DNA polymerase 
per reaction. The samples were boiled for 5 min to disrupt the phage 
particles before addition of the Taq DNA polymerase. Each cycle 
consisted of 1 min denaturing at 95°C, 2 min annealing at 52°C and 
3 min extension at 72°C and a final 10 min extension at 72°C. Either 
lui or 0.5ul of undiluted cDNA library was used as the target for the 
PCR reactions and all reactions were carried out in duplicate. 
2.4. Genetic mapping 
A PCR-based assay was developed using primers Ml (5'-AAGA-
TATTCACACCCTGGCACAGC-3') and M2 (5'-CACCAGCA-
GAATTTTCAAGAGCC-3') that detected the presence of the human 
SRP72 gene in an inter-species somatic cell hybrid panel. Reactions 
were carried out in a 40|il reaction volume with 33 cycles of amplifi-
cation, each consisted of 1 min denaturing at 95°C, 2 min annealing at 
62°C and 3 min extension at 72°C and a final 10 min extension at 
72°C. The PCR products amplified were analysed by electrophoresis 
in 4% agarose gels and visualised using ethidium bromide staining. All 
reactions were carried out in triplicate. 
2.5. Western analysis 
50 ug samples of human islet protein were subjected to SDS-poly-
acrylamide gel electophoresis through a 7.5% acrylamide gel for 90 
min at 150 V. The protein was transferred from the gel to a poly-
vinylidene difluoride membrane using a semi-dry electroblotter. Incu-
bation of the membrane with a CaM kinase II specific antibody was 
carried out overnight at 4°C. The presence of CaM kinase II protein 
on the membrane was then detected using the ECL chemilumines-
cence system (Amersham Life Sciences) according to the manufactur-
er's instructions. The primary antibody used was a rabbit polyclonal 
IgG (Upstate Biotechnology, Lake Placid, USA) raised against two 
epitopes; (1) sequence = CTRTDEYQLFEEL, (residues 7-20 of rat 
CaM kinase II 5 isoform, and (2) sequence = EETRVWHRRDG-
KWQNVHFHC (residues 514-533 of rat CaM kinase II ß isoform). 
The amino acid sequences of these regions of CaM kinase II are 70-
90% homologous to corresponding regions in the isoforms of CaM 
kinase II (y and ß3) expressed in human islets [20]. 
3. Results 
3.1. Cloning of a novel isoform of human islet CaM kinase II 
By screening a human islet c D N A library we previously 
isolated a partial c D N A clone encoding the y isoform of 
C a M kinase II [19]. To obtain full length sequence we now 
have used R A C E to amplify the 3 ' end of the human C a M 
kinase II y gene from human islet R N A . Full length c D N A 
sequences were then deduced from the overlapping sequences 
of the R A C E products and the partial c D N A clone. Two 
sequences were identified as the YB [7] and YE [21] isoforms 
of C a M kinase II. The 5' sequence of a third R A C E product 
comprised 164 bp which were 99.5% homologous to the se-
quence of all known y isoforms of human C a M kinase II. A 
single base pair variation was observed at position 956 result-
ing in an amino acid change of Ser (AGC) to Asn (AAC). The 
remaining part of the sequence (804 bp) was 93.9% homolo-
gous to a region of the canine gene encoding signal recogni-
tion particle 72 (SRP72; GenBank accession N o . X67813) and 
contained sequence 99.4% homologous to a partial c D N A 
(483 bp) encoding the human SRP72 (GenBank accession 
N o . N55583). The deduced full length c D N A sequence, shown 
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1 ATGGCCACCACCGCCACCTGCACCCGTTTCACCGACGACTACCAGCTCTTCGAGGACCTT 
1 M Ä T T A T C T R F T D 3 Y Q I , F E E L 
6i GGCAAGGGTGCTTTCTGTGTGGTCCGCAC-GTGTGTC-AAGAAAACCTGGACGCAGGAGTAC 
21 G K G A F S V V R R C V K K T S T Q E Y 
121 GCAGCAAAAATCATCAATACCAAGAAATTGTCTGCCCGGGATCACCAGAAACTAGAACGT 
4 1 A A K I I N T K K L S A R D H Q K L E R 
181 GAGGCTCGGATÂTGTGGA0TTCTGAAAGA7CCAAACATCGTGCGCCTCCATGAGAGTATT 
61 £ A R I C R L L K H P N I V R L H D S T 
241 TCTGAAGAAGGGTTTCACGACCTCGTGTTTGACCTTGTTACGGGCGGGGAGCTGTTTGAA 
81 S E E G F H Y L V F D L V T G G E L F E 
301 GACATTGTGGCCAGAGAGTACTACAGTGAAGCAGATGCCAGCCACTGTATACATCAGATT 
1 0 1 D 1 V A R E Y Y S E A D A S H C I H Q 1 
361 CTGGAGAGTGTTAACCACATCCACCAGCATGACATCGTCGACAGGGACCTGAAGCCTGAG 
1 2 1 L E S V N K I H Q H D I V H R D L K P E 
421 AACCTGCTCCTCCCCAGTAAATGCAACCGTCCCGCCGTCAAGCFGGCTGATTTTGGCOTA 
1 4 1 N L L L A S K C K G A A V K L A D F G L 
4 81 GCCATCGAAGTACAGGGAGAGCAGCAGGCTTGGTTTGGTTTTGCTGGCACCCCAGGTTAC 
161 A I E V Q G E Q Ç A K F G F A G T P G Y 
541 TTGTCCCGTGAGGTCTTGAGGAAAGATCCCTATGGAAAACC1GTGGATÄTCTGGGCCTGC 
1 8 1 L 5 P E V L R K D P Y G K P V D 1 W A C 
601 GGGCrCATCCTGTATATCGTCCTGGTGGGCTATCCTCCCTTCTGGGATGAGGATCAGCAC 
2 01 G V T L Y 1 L L V G Y P P F W D E D Q 11 
661 AAGCTGTATCAGCAGATCAAGGCTGGAGCCTATGATTTCCCATCACCAGAATGGGACACG 
2 2 1 K L Y Q Q I K Ä G A Y D F P S P E W D T 
721 GTAACTCCTGAAGCCAAGAACTTGATCAACCAGATGCTGAGCATAAACCCAGCAAAGCGC 
241 V T P E A K N L 1 N Q M L T - N P A K R 
'81 ATCACGGCTGACCAGGCTCTCAAGCACCCGTGGGTCTGTCAACGATCCACGGTGGCATCC 
261 I T A D Q A L K H P W V C Q R S T V A S 
841 ATGATGGATCGTGAGGAGACTGTGGAGTGTT7GGGC2AA3TTCAATGCCCGG7iGAAAACTG 
281 M M H R Q E T V E C I. R K F N A R R K L 
901 AAGGGTC-CCATCCTCACGACCATGCTTGTCTCCAGGAACTTCTCAGCrGCCAAAAACCTA 
301 K G A I L T T M L V S R K F S A A K N L 
961 TTGAACAAGAAGTCGGATGGCGGTGTCAAGCCAAGAAAGAACTAGAAGCTATAGAATrTA 
321 L N K K S D G G V K P *R N N Y K L * 
1021 AC7\AAGCTTTACTTGCTATGTACACAAACCAGGCGGAACAATGCCGCAAAATATCTCCCA 
1081 GTTTACAGTCCCAAAGTCCCG/lGCATCTCTTACCGGTGTTAATCGAAGCTGCCCAGCTCT 
■] 4 1 GCCGTGAAAAGCAGCACACAAAAGCAATAGAGCTGCTTCAGGAATTTTCAGA'l'CAGCATC 
1201 CAGAAA^.TGGAGGTGAAATTAAGCTGACCATGGCAGAGTTCAAAATTTCTCAAGGTAATA 
12 61 ""'TTGTAAAGGATG1TTÄA1ATTGAGAAGGAGAGAGGAGTTAAAGCATAAACCAGGCATGG 
1321 lATCTGCATTAGTTACCATGTATAGCCATGAAGAAGATATTGATAGïGCCATTGAGGTCT 
;: 381 7CACACAAGCTATCCAGTGGTATCAAAACCATCAGCCAAAATCTCCTNCTCATTTGTGCT 
'.441 TGATAAGAGAAGCTGCAAACTTCAAACTCAAATATGGGCGGÄAC-AAGC-AGGCÄATTAGTG 
15 01 ACGTAGAACAGCTGTGGAAACAAAATCCAAAAGATATTCACACCCTCGCACAGCTTATTT 
1561 CTGCrTACTCACTTGTAGATCCAGAGAAAGGGAAAGGGCTTAGTAAACACTTGCCATCGT 
1621 CAGATAGTATGTCACTAAAAG7AGATGTTGAGGCÏCTTGAAAAÏTCTGCTGGÏGCTACAT 
1 681 ACATTCGGAAGAAGGGTGGAAAAGTTACÏGGAGATAGTCAACCAAAGGAACAAGGACAGG 
17 41 GAGATT7GAAAAAGTAC-CAAAAAAAAAAAAAAAAÄAACTGAAÄGCTATCGATTCTGC 
Fig. 1. Nucleotide sequence of the human ygRP isoform of CaM kin-
ase II. The position where the sequence of the human y CaM kinase 
II gene ends and the sequence of the human SRP72 gene begins is 
indicated by an arrow. Amino acids with solid underline are pre-
dicted autophosphorylation sites based on similarity to a CaM kin-
ase II and the calmodulin binding site is underlined in dashes [7]. 
in Fig. 1, is predicted to code for a truncated form of C A M 
kinase II of 330 amino acids with a molecular mass of 37 
kDa. This novel isoform of C a M kinase II which we designate 
YSRP contains the catalytic and regulatory regions of y C a M 
kinase II plus an additional 6 novel amino acids before a stop 
codon is reached. Homology searches were performed for this 
new region of C a M kinase II ( R N N Y K L ) ; neither BLAST 
nor Motifs searches revealed any significant homology to any 
known protein motifs. 
The following criteria were used to establish that the R A C E 
products we obtained were genuine. (1) They were generated 
from four independent reactions. (2) They were primed from 
the expected position in the R N A (site at which primer P2 
binds, see Section 2). (3) Their sequences overlapped that of 
the library clone previously obtained (see above). (4) They 
contained a poly-A tail plus the sequence of the anchor pri-
mer. 
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Fig. 2. Comparison of the nucleotide sequence of the YSRP RACE 
product with that of the PCR product amplified from a human islet 
cDNA library. The part of the sequence spanning the junction be-
tween the y CaM kinase II sequence and the SRP72 sequence is 
shown and the junction indicated by an arrow. 
The sequence of the novel RACE product was submitted to 
GenBank and assigned the accession No. U81554. 
3.2. PCR 
The polymerase chain reaction was used to confirm the 
expression of a YSRP-like cDNA species in the human islet 
cDNA library. A band of the expected size (434 bp) was 
amplified. This band was isolated and subcloned and plasmids 
containing inserts of the expected size were identified by re-
striction enzyme digestion and sequenced. The nucleotide se-
quence of these clones was 100% identical to the nucleotide 
sequence of the clone isolated by the RACE method (Fig. 2). 
3.3. Genetic mapping 
In an attempt to elucidate if the YSRP cDNA was produced 
by alternative splicing of a single large transcript from one 
gene or by some other method, we mapped the human SRP72 
gene. A monochromosomal hybrid mapping panel was used 
to map the YSRP gene. The basis of the mapping strategy was 
that SRP72 specific primers MI and M2 would amplify bands 
of different sizes from human and rodent DNA, allowing us 
to determine if the gene coding for SRP72 was present in the 
human DNA contained within each hybrid. As each hybrid 
contained the DNA from only one human chromosome, we 
could determine which human chromosome contained the 
gene coding for SRP72. Primers MI and M2 amplified a single 
band of size 144 bp from total human genomic DNA (con-
taining all chromosomes), a much larger band from total 
hamster genomic DNA and no product from total mouse 
genomic DNA (lanes 1, 2 and 3 in Fig. 3). In Fig. 3, lanes 
f, g, 1-p, t-v and w contain PCR reactions carried out with 
hybrids containing DNA from individual human chromo-
somes 6, 7, 12-16, 20-22 and X, respectively, on a mouse 
genetic background. Using primers MI and M2 no product 
was amplified from these samples (Fig. 3). Lanes a-e, h-k, q, 
s, t and x (Fig. 3) contained PCR product amplified from 
hybrids containing DNA from individual human chromosome 
1-5, 8-11, 17, 19-20 and Y, respectively, on a hamster genetic 
background. Using primers MI and M2 a single band corre-
sponding in size to the hamster genetic background was am-
plified from these hybrids. Lane j contained DNA from hu-
man chromosome 10 only, on a hamster genetic background. 
As only one band corresponding in size to the hamster genetic 
background was amplified from this hybrid and no band cor-
responding in size to the human gene (144 bp), we conclude 
that the gene encoding SRP72 is not present on human chro-
mosome 10. Lane DL18TS (Fig. 3) contained the PCR prod-
uct from a reaction carried out with hybrid DL18TS. This 
hybrid contained the DNA from human chromosome 18 on 
a hamster genetic background [22]. Two bands were amplified 
from hybrid DL18TS - a band of the size expected for the 
human SRP72 gene and a band of the size expected for the 
hamster gene. It was concluded that the human SRP72 gene is 
located on human chromosome 18. 
3.4. Western analysis 
Although we had established the expression of a YSRP 
cDNA in human islets we did not know if this cDNA was 
stable and if it would be transcribed to produce a protein 
product. On Western analysis with a CaM kinase II specific 
antibody and human islet protein, four bands were detected 
(Fig. 4). The molecular weight of the smallest band was de-
Fig. 3. Genetic mapping of the human SRP72 gene using the monochromosomal hybrid mapping panel. The first three lanes 1, 2 and 3 contain 
PCR products amplified from the control reactions, 1, human genomic DNA; 2, hamster genomic DNA; and 3, mouse genomic DNA. Lanes 
a-q and s-v, w and x contain PCR products amplified from the monochromosomal hybrids containing DNA from individual human chromo-
somes 1-17, 19-22, X and Y, respectively. Lane DL18TS contains the product amplified from hybrid DL18TS. Lane 4 is the negative control 
containing PCR reaction carried out using no target DNA (water). The sizes (bp) of the nucleic acid markers are indicated on the left. 
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Fig. 4. Western blot of human islet protein using a CaM kinase II 
specific antibody. Lane A contains a negative control (water) and 
lanes B and C contain human islet protein. The sizes of the appro-
priate molecular weight markers are indicated on the left. 
termined to be between 29 and 49 kDa by reference to the 
molecular weight standards used. This band was identified as 
a YsRP-like isoform of CaM kinase II, based on the following 
criteria: (1) it was immunoreactive with the CaM kinase II 
specific antibody ; (2) its apparent molecular weight was small-
er than that of any other isoform of CaM kinase II thus far 
identified; and (3) it was within the range of the predicted 
molecular weight of YSRP (37 kDa). The gel was slightly over-
loaded in order to show the presence of other full length iso-
forms of CaM kinase II in human islets. Three further bands 
observed in the size range 49-82 kDa are thought to represent 
the ß3 (65 kDa), YE (61 kDa) and ye (57 kDa) isoforms of 
CaM kinase II also shown to be present in human islets [20]. 
4. Discussion 
All isoforms of CaM kinase II can be divided into three 
functional domains - an N-terminal catalytic region, and a C-
terminal association domain flank an intervening variable re-
gion [5]. The association domain may not have a catalytic or 
regulatory role but is thought to play a part in holoenzyme 
formation [23]. The novel truncated isoform (YSRP) of CaM 
kinase II demonstrated here in human islets of Langerhans is 
predicted to contain the catalytic and regulatory domains, the 
calmodulin-binding site and the auto-inhibitory domain of the 
kinase (Fig. 1). Therefore we expect CaM kinase II YSRP to 
have similar catalytic properties and be regulated in the same 
manner as the holoenzyme. However as this isoform lacks an 
association domain it is likely to exist as a monomer. Con-
sistent with these ideas is the fact that a 30-kDa active frag-
ment of CaM kinase II produced by chymotryptic digestion 
exists as a monomer and phosphorylates synapsin I at the 
same site as does the native CaM kinase II [23]. Expression 
studies will be needed to confirm these predictions and to 
assess the function of the 6 amino acids (RNNYKL) in 
CaM kinase II YSRP derived from the SRP72 gene. The ex-
pression of a truncated CaM kinase II may have important 
functional consequences for targeting the enzyme. 
Using a rodent-human somatic cell hybrid panel the human 
SRP72 gene was mapped to human chromosome 18. The 
CaM kinase II Y gene has previously been mapped to human 
chromosome 10 [24]. Thus we conclude that the YSRP C D N A 
could not have resulted from the alternative splicing of a 
single large transcript from one chromosome. It may however 
have resulted from a chromosomal translocation event or 
more probably from trans-splicing. The YB and Yc isoforms 
of CaM kinase II differ from each other by an insertion/dele-
tion of 69 base pairs at position 1012 (YB) [7]. As these two 
isoforms of the kinase are thought to result from alternative 
splicing of a single RNA transcript, the nucleotides close to 
position 1012 of YB may represent a splice junction. The 
SRP72 gene is joined to the CaM kinase II gene at a position 
corresponding to nucleotide 1014 in YB and therefore may be 
at a splice junction. Although in both cases the consensus 
exon/intron boundary sequence can be identified ( C A A G / 
G T A G A G T ) , the consensus sequence for an intron/exon boun-
dary ((Tc)nNCTAG/G) can not [25]. The intron/exon structure 
of neither the SRP72 gene nor the CaM kinase II Y gene has 
been elucidated. The identification of the splice donor and 
acceptor sites of the CaM kinase II and SRP72 genes will 
need to be investigated, in order to confirm that the YSRP 
fusion RNA expressed in human islets is formed by trans-
splicing. 
Multiple isoforms of CaM kinase II are expressed in differ-
ent tissue types. These various isoforms differ in insertions 
and deletions within the variable and association domains of 
the protein and are thought to be produced by alternative 
splicing of single RNA transcripts [6,7]. The present study 
suggests that trans-splicing may represent an alternative proc-
ess by which isoforms of CaM kinase II may be produced in 
normal adult tissue. To date the expression of cDNA pro-
duced by trans-splicing appears to be limited to proteins of 
undetermined function in diseased human adult tissue [26], 
transgenic mice [27] or rat fetal tissues [28]. We believe that 
YSRP may represent the first example of trans-splicing produc-
ing a potentially functional protein in normal adult human 
tissue. 
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